In Case You Missed It: Biologic Treatment of Systemic Juvenile Ideopathic Arthritis

Drs Li and Geskey have disclosed no financial relationship relevant to this commentary. This commentary does not contain a discussion of an unapproved/investigative use of a commercial product/device. Investigators from multiple pediatric rheumatology centers conducted an international double-blind, placebo-controlled randomized clinical trial of tocilizumab (an anti-interleukin- 6 receptor antibody) for the treatment of systemic juvenile idiopathic arthritis (JIA).1 Patients were evaluated for response or flare according to JIA American College of Rheumatology (ACR) criteria, in which a JIA ACR30 response means the patient had 30% or greater improvement in at least 3 of 6 parameters (number of joints …